Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
The authors describe the use of gabapentin in the treatment of 4 outpatients with dementia-associated agitation. On the basis of clinical case reports and the Overt Agitation Severity Scale, all 4 patients had reduced agitation with gabapentin. Three of 4 patients were successfully titrated to a full dose of 2,400mg/day. These findings suggest a possible role for gabapentin in the behavioral In a 24-patient case series from retrospective chart review, the authors examined the use of gabapentin for the treatment of aggressive and agitated behaviors in nursing home patients with a DSM-IV diagnosis of dementia. FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease. May 11, 2023. Accessed October 2023. Howard RJ, Juszczak E, Ballard CG, et al. and the CALM-AD Trial Group. Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med. 2007 Oct 4;357(14):1382-92. doi: 10.1056/NEJMoa066583. Which medications are effective at decreasing agitation in patients with dementia? Selective serotonin reuptake inhibitors (SSRIs) and risperidone (Risperdal) are moderately effective The authors describe the use of gabapentin in the treatment of 4 outpatients with dementia-associated agitation. On the basis of clinical case reports and the Overt Agitation Severity Scale, all 4 patients had reduced agitation with gabapentin. Three of 4 patients were successfully titrated to a ful Methods: Following PRISMA guidelines, we systematically reviewed evidence for gabapentin and pregabalin against BPSD symptoms of agitation or aggression in any dementia, using six databases (Pubmed, CINHL, PsychINFO, HealthStar, Embase, and Web of Science). The authors describe the use of gabapentin in the treatment of 4 outpatients with dementia-associated agitation. On the basis of clinical case reports and the Overt Agitation Severity Scale, all 4 patients had reduced agitation with gabapentin. Agitation is difficult to manage in dementia patients with negative impact on patients’ health. Gabapentinoids are well tolerated in the elderly with promising results in agitated patients. Pregabalin can be a useful treatment option with its rapid action and efficacy in lower doses. 1. Introduction. Neuropsychiatric symptoms are common in dementia, but may be under-reported by patients and families . Screening for agitation and other neuropsychiatric symptoms in patients with dementia should be done at regular follow-up visits . We ask both caregivers and patients explicit questions regarding such symptoms, for example, "Does the patient The clinic's database was searched to identify patients diagnosed with dementia (all types) and agitation, and treated with either gabapentin or pregabalin between January 2019 and April 2023. Medical records, brain images, and laboratory findings were reviewed retrospectively. Agitation is common among older adults with dementia; its origin may be multi-factorial, and it is often difficult to treat. In this paper, we summarize current knowledge and offer considerations on pharmacologic management of behavioral and psychological symptoms of dementia (BPSD). Keywords: agitation, dementia, hyperkinetic delirium, Alzheimer's Disease, Dementia with Lewy Bodies, Frontotemporal Dementia, Vascular Dementia, COVID-19 Introduction Agitation is a common behavioral disturbance featuring exaggerated motor activity and verbal and/or physical aggressiveness, severe enough to impair social relations and daily In most of the reviewed cases, gabapentin was reported to be a well tolerated and effective treatment for BPSD. However, two case reports in which gabapentin was used in the context of agitation in dementia with Lewy bodies questioned the appropriateness of gabapentin for all types of dementia-related agitation. We would like to show you a description here but the site won’t allow us. Rating Anxiety in Dementia Scale (6). Following this intervention, subsequent episodes of agitation were limited to delirium, especially during UTIs. The second case is a 97-year-old male with mixed Alzheimer’s and vascular dementia who continued to have breakthrough agitation despite being treated with trazodone 25mg nightly. Aim: To evaluate low dose gabapentin in treatment of disruptive behavioral symptoms in patients with moderate- severe dementia with Lewy bodies. Findings: Improvement in symptoms seen by clinician and caregivers supported by changes on respective scales. The newer anticonvulsants gabapentin and lamo-trigine are being studied with this population. To date, little evidence is available on their use in treating agitation in patients with dementia, although there is evidence of their usefulness in other patient populations for agitation (37–40). They are to be used with caution. The first case report published about the use of gabapentin in agitation in dementia was by Regan and Gordon 50. In this case, the average dose used was 600 mg day −1. The patient, a woman aged 68 with Alzheimer's dementia (AD) had less agitation as per nursing observational reports after 12 weeks of treatment. Several case reports describe using gabapentin, an anti-epileptic and FDA-approved treatment for neuropathic pain, as an off-label treatment for BPSD. BPSD in some patients may be driven by unreported neuropathic pain, which gabapentin can treat effectively. We present the case of a patient with incipient vascular dementia accompanied by nocturnal agitation, which was successfully treated with gabapentin. Gabapentin appears to be useful and well-tolerated in this indication.
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |